Kura Oncology (NASDAQ:KURA) Shares Down 2.7% – What’s Next?

Kura Oncology, Inc. (NASDAQ:KURA) fell 2.7% during trading on Monday . The stock traded as low as $7.69 and last traded at $7.63. 44,364 shares were traded during trading, a decline of 96% from the average session volume of 1,057,173 shares. The stock had previously closed at $7.84.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on KURA. Scotiabank dropped their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Wedbush restated an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. Finally, StockNews.com downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Price Performance

The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business’s 50-day simple moving average is $7.83 and its two-hundred day simple moving average is $12.21. The firm has a market cap of $574.98 million, a price-to-earnings ratio of -3.02 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. As a group, research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,729 shares of company stock valued at $92,307. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KURA. Barclays PLC grew its stake in Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after acquiring an additional 84,563 shares during the period. SG Americas Securities LLC acquired a new stake in Kura Oncology in the 4th quarter valued at $436,000. Moody Aldrich Partners LLC increased its stake in Kura Oncology by 42.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock valued at $1,251,000 after purchasing an additional 42,712 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after buying an additional 2,076 shares during the last quarter. Finally, Jennison Associates LLC bought a new position in shares of Kura Oncology in the fourth quarter valued at $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.